Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Heart Failure | Review

Heart failure with preserved ejection fraction based on aging and comorbidities

Authors: Ying Lin, Shihui Fu, Yao Yao, Yulong Li, Yali Zhao, Leiming Luo

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

Heart failure (HF) with preserved ejection fraction (HFpEF) is a leading cause of hospitalizations and mortality when diagnosed at the age of ≥ 65 years. HFpEF represents multifactorial and multisystemic syndrome and has different pathophysiology and phenotypes. Its diagnosis is difficult to be established based on left ventricular ejection fraction and may benefit from individually tailored approaches, underlying age-related changes and frequent comorbidities. Compared with the rapid development in the treatment of heart failure with reduced ejection fraction, HFpEF presents a great challenge and needs to be addressed considering the failure of HF drugs to improve its outcomes. Further extensive studies on the relationships between HFpEF, aging, and comorbidities in carefully phenotyped HFpEF subgroups may help understand the biology, diagnosis, and treatment of HFpEF. The current review summarized the diagnostic and therapeutic development of HFpEF based on the complex relationships between aging, comorbidities, and HFpEF.
Literature
1.
Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.PubMedCrossRef
2.
Paulus W, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and Remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.PubMedCrossRef
3.
Fonarow GC, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768–77.PubMedCrossRef
4.
Kitzman DW, Shah SJ. The HFpEF obesity phenotype: the elephant in the room. J Am Coll Cardiol. 2016;68:200–3.PubMedCrossRef
5.
Solomon SD, et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609–20.PubMedCrossRef
6.
Figtree GA, et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes: results from the CANVAS program. Circulation. 2019;139:2591–3.PubMedCrossRef
7.
van Woerden G, Gorter TM, Westenbrink BD, Willems TP, van Veldhuisen DJ, Rienstra M. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. Eur J Heart Fail. 2018;20:1559–66.PubMedCrossRef
8.
Mahajan R, et al. Electroanatomical remodeling of the atria in obesity: impact of adjacent epicardial fat. JACC Clin Electrophysiol. 2018;4:1529–40.PubMedCrossRef
9.
Shah SJ, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39:3439–50.PubMedPubMedCentralCrossRef
10.
Kanagala P, et al. Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction. JACC Cardiovasc Imaging. 2018;12:2291–301.CrossRef
11.
Siebermair J, et al. Atrial fibrosis in non-atrial fibrillation individuals and prediction of atrial fibrillation by use of late gadolinium enhancement magnetic resonance imaging. J Cardiovasc Electrophysiol. 2019;30:550–6.PubMedCrossRef
12.
13.
14.
Fu S, Xie L, Li D, Ye P, Luo L. The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure. Clin Interv Aging. 2015;10:359–65.PubMedPubMedCentralCrossRef
15.
Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507–15.PubMedCrossRef
16.
Kaye DM, Marwick TH. Impaired right heart and pulmonary vascular function in HFpEF: time for more risk markers? JACC Cardiovasc Imaging. 2017;10(10 Pt B):1222–4.PubMedCrossRef
17.
Iyngkaran P, Anavekar NS, Neil C, Thomas L, Hare DL. Shortness of breath in clinical practice: a case for left atrial function and exercise stress testing for a comprehensive diastolic heart failure workup. World J Methodol. 2017;7(4):117–28.PubMedPubMedCentralCrossRef
18.
Lam CSP, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13(1):18–28.PubMedCrossRef
19.
Frantz S, et al. The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientifc statement from the Working Group on Myocardial Function of the ESC. Eur J Heart Fail. 2018;20(3):445–59.PubMedCrossRef
20.
Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131:550–9.PubMedCrossRef
21.
Gevaert AB, Boen JRA, Segers VF, Van Craenenbroeck EM. Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology. Front Physiol. 2019;10:638.PubMedPubMedCentralCrossRef
22.
Mohammed SF, et al. Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation. 2014;130:2310–20.PubMedPubMedCentralCrossRef
23.
Zile MR, et al. Myocardial stifness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131(14):1247–59.PubMedPubMedCentralCrossRef
24.
Krüger M, et al. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res. 2009;104(1):87–94.PubMedCrossRef
25.
van Heerebeek L, Franssen CPM, Hamdani N, Verheugt FWA, Somsen GA, Paulus WJ. Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep. 2012;9(4):293–302.PubMedCrossRef
26.
Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol. 2018;71:2360–72.PubMedCrossRef
27.
Packer M. The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction. Eur J Heart Fail. 2018;20:1567–9.PubMedCrossRef
28.
Greulich S, et al. Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction. Circulation. 2012;126:2324–34.PubMedCrossRef
29.
Fu S, et al. Overall and abdominal obesity indicators had different association with central arterial stiffness and hemodynamics independent of age, sex, blood pressure, glucose, and lipids in Chinese community-dwelling adults. Clin Interv Aging. 2013;8:1579–84.PubMedPubMedCentralCrossRef
30.
Mazurek T, et al. Relation of proinflammatory activity of epicardial adipose tissue to the occurrence of atrial fibrillation. Am J Cardiol. 2014;113:1505–8.PubMedCrossRef
31.
Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fbrosis in the pressure-overloaded heart. Cardiovasc Res. 2011;89(2):265–72.PubMedCrossRef
32.
de Boer RA, et al. Towards better defnition, quantifcation and treatment of fbrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur J Heart Fail. 2019;21(3):272–85.PubMedCrossRef
33.
Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39(30):2780–92.PubMedCrossRef
34.
Rich MW, Kitzman DW. Heart failure in octogenarians: a fundamentally different disease. Am J Geriatr Cardiol. 2000;9:97–104.
35.
Upadhya B, Haykowsky MJ, Eggebeen J, Kitzman DW. Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2015;12:205–14.PubMedPubMedCentralCrossRef
36.
Ather S, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005.PubMedPubMedCentralCrossRef
37.
Murad K, Kitzman D. Frailty and multiple comorbidities in the elderly patient with heart failure: implications for management. Heart Fail Rev. 2011;17:581–8.CrossRef
38.
Franssen C, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2015;4:312–24.PubMedCrossRef
39.
Pedone C, Roshanravan B, Scarlata S, Patel KV, Ferrucci L, Incalzi RA. Longitudinal association between serum leptin concentration and glomerular filtration rate in humans. PLoS ONE. 2015;10:e0117828.PubMedPubMedCentralCrossRef
40.
Bouthoorn S, et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection fraction in men and women with type 2 diabetes: a systematic review and meta-analysis. Diab Vasc Dis Res. 2018;15:477–93.PubMedCrossRef
41.
Schelbert EB, et al. Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome. JAMA Cardiol. 2017;2:995–1006.PubMedPubMedCentralCrossRef
42.
Cheng RK, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168:721–30.PubMedCrossRef
43.
Packer M. Do most obese people with exercise intolerance and a normal ejection fraction have treatable heart failure? Am J Med. 2018;131:863–4.PubMedCrossRef
44.
Packer M. The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range. Eur J Heart Fail. 2019;21:156–62.PubMedCrossRef
45.
Fu S, Jiao J, Guo Y, Zhu B, Luo L. N-terminal pro-brain natriuretic peptide levels had an independent and added ability in the evaluation of all-cause mortality in older Chinese patients with atrial fibrillation. BMC Geriatr. 2019;19(1):56.PubMedPubMedCentralCrossRef
46.
Sramko M, et al. Independent effect of atrial fibrillation on natriuretic peptide release. Clin Res Cardiol. 2019;108:142–9.PubMedCrossRef
47.
Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. Diabetes Care. 2014;37:2899–908.PubMedCrossRef
48.
Yancy CW, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure. J Am Coll Cardiol. 2017;70:776–803.PubMedCrossRef
49.
Gupta DK, et al. Effective anticoagulation with factor Xa next generation in AF–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF–IMI 48) Echocardiographic Study Investigators. The prognostic significance of cardiac structure and function in atrial fibrillation: the ENGAGE AF-TIMI 48 echocardiographic substudy. J Am Soc Echocardiogr. 2016;29:537–44.PubMedPubMedCentralCrossRef
50.
Obakata M, Kane GC, Reddy YNV, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction a simultaneous invasive-echocardiographic study. Circulation. 2017;135:825–38.CrossRef
51.
Nagueh SF, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314.PubMedCrossRef
52.
Dryer K, et al. Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2018;314(5):H1033–42.PubMedPubMedCentralCrossRef
53.
Yancy CW, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282–93.PubMed
54.
Taqueti VR, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018;39(10):840–9.PubMedCrossRef
55.
Hussain N, et al. Pulmonary hypertension in patients with heart failure and preserved ejection fraction: differential diagnosis and management. Pulm Circ. 2016;6(1):3–14.PubMedPubMedCentralCrossRef
56.
Shah AM, Solomon SD. Phenotypic and pathophysiological heterogeneity in heart failure with preserved ejection fraction. Eur Heart J. 2012;33:1716–7.PubMedCrossRef
57.
Pieske B, et al. How to diagnose heart failure with preserved ejection fraction: the HFAPEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297–317.PubMedCrossRef
58.
Haykowsky M, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014;113:1211–6.PubMedPubMedCentralCrossRef
59.
Kitzman DW, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomised clinical trial. JAMA. 2016;315:36–46.PubMedPubMedCentralCrossRef
60.
Haass M, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction/clinical perspective. Circ Heart Fail. 2011;4:324–31.PubMedPubMedCentralCrossRef
61.
Rodriguez Flores M, Aguilar Salinas C, Piché ME, Auclair A, Poirier P. Effect of bariatric surgery on heart failure. Expert Rev Cardiovasc Ther. 2017;15:567–79.PubMedCrossRef
62.
63.
Pathak RK, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65:2159–69.PubMedCrossRef
64.
Sundström J, Bruze G, Ottosson J, Marcus C, Näslund I, Neovius M. Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment. Circulation. 2017;135:1577–85.PubMedPubMedCentralCrossRef
65.
Reeves GR, et al. A novel rehabilitation intervention for older patients with acute decompensated heart failure: the REHAB-HF pilot study. JACC Heart Fail. 2016;5:359–66.CrossRef
66.
Dunlay SM, Roger VL, Redfeld MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591–602.PubMedCrossRef
67.
Tschöpe C, et al. Heart failure with preserved ejection fraction: current management and future strategies: expert opinion on the behalf of the Nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG). Clin Res Cardiol. 2018;107(1):1–19.PubMedCrossRef
68.
Williams B, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.PubMedCrossRef
69.
Williamson JD, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial. JAMA. 2016;315:2673–82.PubMedPubMedCentralCrossRef
70.
Yancy CW, et al. 2013 ACCF/AHA guideline for the management of heart-failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.PubMedCrossRef
71.
Gandhi SK, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344:17–22.PubMedCrossRef
72.
Marrouche NF, et al. Catheter ablation for atrial fbrillation with heart failure. N Engl J Med. 2018;378(5):417–27.PubMedCrossRef
73.
Lam CS, et al. Atrial fibrillation in heart failure with preserved ejection fraction: association with exercise capacity, left ventricular filling pressures, natriuretic peptides, and left atrial volume. JACC Heart Fail. 2016;5:92–8.PubMedCrossRef
74.
Eitel C, et al. Atrial fbrillation ablation strategies and outcome in patients with heart failure: insights from the German ablation registry. Clin Res Cardiol. 2019;108(7):815–23.PubMedCrossRef
75.
Machino-Ohtsuka T, et al. Efficacy, safety, and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2013;62:1857–65.PubMedCrossRef
76.
77.
Anker SD, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-defcient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20(1):125–33.PubMedCrossRef
78.
Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA. The infuence of iron defciency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail. 2016;18(7):762–73.PubMedCrossRef
79.
Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12(2):70–88.PubMedCrossRef
80.
Pahlavani M, Kalupahana NS, Ramalingam L, Moustaid-Moussa N. Regulation and functions of the renin–angiotensin system in white and brown adipose tissue. Compr Physiol. 2017;7:1137–50.PubMedPubMedCentralCrossRef
81.
Ghanim H, Monte S, Caruana J, Green K, Abuaysheh S, Dandona P. Decreases in neprilysin and vasoconstrictors and increases in vasodilators following bariatric surgery. Diabetes Obes Metab. 2018;20:2029–33.PubMedCrossRef
82.
Wang Q, et al. The crucial role of activin A/ALK4 pathway in the pathogenesis of Ang-II-induced atrial fibrosis and vulnerability to atrial fibrillation. Basic Res Cardiol. 2017;112:47.PubMedCrossRef
83.
Goossens GH, et al. Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. PLoS ONE. 2012;7:e39930.PubMedPubMedCentralCrossRef
84.
Massie BM, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.PubMedCrossRef
85.
Yip GWK, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94(5):573–80.PubMedCrossRef
86.
Seferovic PM, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(10):1169–86.PubMedCrossRef
87.
88.
Pitt B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.PubMedCrossRef
89.
Hunt SA, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391–479.PubMed
90.
Fukuta H, Goto T, Wakami K, Ohte N. The effect of betablockers on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. Int J Cardiol. 2017;228:4–10.PubMedCrossRef
91.
Belge C, et al. Enhanced expression of beta3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation. 2014;129(4):451–62.PubMedCrossRef
92.
93.
Domínguez E, et al. Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction. ESC Heart Fail. 2018;5:579–85.PubMedPubMedCentralCrossRef
94.
Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62:1330–8.PubMedCrossRef
95.
Sartipy U, Savarese G, Dahlström U, Fu M, Lund LH. Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. Eur J Heart Fail. 2019;21:471–9.PubMedCrossRef
96.
Whitbeck MG, et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J. 2013;34:1481–8.PubMedCrossRef
97.
Khazanie P, Hellkamp AS, Fonarow GC, Curtis LH, Al-Khatib SM, Hernandez AF. Permanent pacemaker use among patients with heart failure and preserved ejection fraction: findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. Am Heart J. 2018;198:123–8.PubMedCrossRef
98.
Voskoboinik A, et al. Cardioversion of atrial fibrillation in obese patients: results from the Cardioversion-BMI randomized controlled trial. J Cardiovasc Electrophysiol. 2019;30:155–61.PubMedCrossRef
99.
Mareev Y, Cleland JG. Should B-blockers be used in patients with heart failure and atrial fibrillation? Clin Ther. 2015;37:2215–24.PubMedCrossRef
100.
Eschalier R, et al. Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. Hypertension. 2014;63:740–6.PubMedCrossRef
101.
Thomas L, Marwick TH, Popescu BA, Donal E, Badano LP. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:1961–77.PubMedCrossRef
102.
Hirai T, Cotseones G, Makki N, Agrawal A, Wilber DJ, Barron JT. Usefulness of left ventricular diastolic function to predict recurrence of atrial fibrillation in patients with preserved left ventricular systolic function. Am J Cardiol. 2014;114:65–9.PubMedCrossRef
103.
Ling LH, et al. Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation. Heart Rhythm. 2013;10:1334–9.PubMedCrossRef
104.
Fukumoto K, et al. Comparison of preexisting and ablation-induced late gadolinium enhancement on left atrial magnetic resonance imaging. Heart Rhythm. 2015;12:668–72.PubMedCrossRef
105.
Packer M. Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation. Eur Heart J. 2019;40:1873–9.PubMedPubMedCentralCrossRef
106.
Urey MA, et al. Stiff left atrial syndrome after multiple percutaneous catheter ablations: role for invasive hemodynamic exercise testing. Circ Heart Fail. 2017;10:e003885.PubMedCrossRef
107.
Parisi V, et al. Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue. Int J Cardiol. 2019;274:326–30.PubMedCrossRef
108.
Yang Q, Qi X, Dang Y, Li Y, Song X, Hao X. Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing. BMC Cardiovasc Disord. 2016;16:142.PubMedPubMedCentralCrossRef
109.
Flint AC, et al. Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation. Stroke. 2017;48:1788–94.PubMedCrossRef
110.
Preiss D, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J. 2015;36:1536–46.PubMedPubMedCentralCrossRef
111.
Fu S, Ping P, Ye P, Luo L. Relationship between drug application and mortality rate in Chinese older coronary artery disease/chronic heart failure patients with and without low glomerular filtration rate. BMC Pharmacol Toxicol. 2019;20(1):44.PubMedPubMedCentralCrossRef
112.
Karayannis G, et al. Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology. 2013;64:173–80.PubMedCrossRef
113.
Solomon SD, et al. Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95.PubMedCrossRef
114.
Fu S, Ping P, Wang F, Luo L. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2.PubMedPubMedCentralCrossRef
115.
Fu S, Ping P, Zhu Q, Ye P, Luo L. Brain natriuretic peptide and its biochemical, analytical, and clinical issues in heart failure: a narrative review. Front Physiol. 2018;9:692.PubMedPubMedCentralCrossRef
116.
Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362(9386):777–81.PubMedCrossRef
117.
Tschöpe C, Van Linthout S. New insights in (inter) cellular mechanisms by heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2014;11(4):436–44.PubMedPubMedCentralCrossRef
118.
Redfeld MM, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015;373(24):2314–24.CrossRef
119.
Borlaug BA, et al. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial. JAMA. 2018;320(17):1764–73.PubMedPubMedCentralCrossRef
120.
Westermann D, et al. Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol. 2009;104(5):499–509.PubMedCrossRef
121.
122.
Redfeld MM, et al. Efect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268–77.CrossRef
123.
Hoendermis ES, et al. Efects of sildenafl on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36(38):2565–73.PubMedCrossRef
124.
Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafl improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4(1):8–17.PubMedCrossRef
125.
Filippatos G, et al. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail. 2017;19(6):782–91.PubMedCrossRef
126.
Cieslik KA, Trial J, Carlson S, Taffet GE, Entman ML. Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels. FASEB J. 2013;27:1761–71.PubMedPubMedCentralCrossRef
127.
Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019;21:210–7.PubMedCrossRef
128.
Liou YS, Yang FY, Chen HY, Jong GP. Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. PLoS ONE. 2018;13:e0197245.PubMedPubMedCentralCrossRef
129.
Jing Y, Wu F, Li D, Yang L, Li Q, Li R. Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol Cell Endocrinol. 2018;461:256–64.PubMedCrossRef
130.
Chang SH, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014;13:123.PubMedPubMedCentralCrossRef
131.
Yang W, Yang C, Luo J, Wei Y, Wang W, Zhong Y. Adiponectin promotes preadipocyte differentiation via the PPARpathway. Mol Med Rep. 2018;17:428–35.PubMed
132.
Antonopoulos AS, et al. Mutual regulation of epicardial adipose tissue and myocardial redox state by PPAR-/adiponectin signalling. Circ Res. 2016;118:842–55.PubMedPubMedCentralCrossRef
133.
Pallisgaard JL, et al. Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2017;3:140–6.PubMed
134.
135.
136.
Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidine-diones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11:115–28.PubMedCrossRef
137.
Cacciapuoti F, Magro VM, Caturano M, Lama D, Cacciapuoti F. The role of ivabradine in diastolic heart failure with preserved ejection fraction. A Doppler-echocardiographic study. J Cardiovasc Echogr. 2017;27:126–31.PubMedPubMedCentralCrossRef
138.
McMurray JJV, et al. Dapaglifozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.PubMedCrossRef
139.
Maack C, et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. Eur Heart J. 2018;39(48):4243–54.PubMedPubMedCentralCrossRef
140.
Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol. 2017;2(9):939–40.PubMedCrossRef
141.
Pabel S, et al. Empaglifozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20(12):1690–700.PubMedCrossRef
142.
143.
Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation. 2008;117(4):574–84.PubMedCrossRef
144.
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.PubMedCrossRef
145.
Graziani F, Varone F, Crea F, Richeldi L. Treating heart failure with preserved ejection fraction: learning from pulmonary fbrosis. Eur J Heart Fail. 2018;20(10):1385–91.PubMedCrossRef
146.
Yamagami K, et al. Pirfenidone exhibits cardioprotective efects by regulating myocardial fbrosis and vascular permeability in pressure-overloaded hearts. Am J Physiol Heart Circ Physiol. 2015;309(3):H512–22.PubMedCrossRef
147.
Hartog JWL, Voors AA, Bakker SJL, Smit AJ, van Veldhuisen DJ. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007;9(12):1146–55.PubMedCrossRef
148.
Kasner M, et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol. 2011;57(8):977–85.PubMedCrossRef
149.
Little WC, Zile MR, Kitzman DW, Hundley WG, O’Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005;11(3):191–5.PubMedCrossRef
150.
151.
152.
Everett BM, et al. Anti-infammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation. 2019;139(10):1289–99.PubMedCrossRef
153.
Bertero E, Maack C. Calcium signaling and reactive oxygen species in mitochondria. Circ Res. 2018;122(10):1460–78.PubMedCrossRef
154.
Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S, Zhang K. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9(2):e002206.PubMedPubMedCentralCrossRef
155.
Daubert MA, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(12):e004389.PubMedCrossRef
156.
Voors AA, et al. Rationale and design of the phase 2b clinical trials to study the efects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. Eur J Heart Fail. 2018;20(11):1601–10.PubMedCrossRef
157.
Parissis JT, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol. 2006;98(11):1489–92.PubMedCrossRef
158.
Grossman NL, Fiack CA, Weinberg JM, Rybin DV, Farber HW. Pulmonary hypertension associated with heart failure with preserved ejection fraction: acute hemodynamic effects of inhaled iloprost. Pulm Circ. 2015;5(1):198–203.PubMedPubMedCentralCrossRef
159.
160.
Wong LL, et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2015;17(4):393–404.PubMedCrossRef
161.
162.
Adamson PB, et al. CHAMPION trial rationale and design: the long-term safety and clinical efcacy of a wireless pulmonary artery pressure monitoring system. J Card Fail. 2011;17(1):3–10.PubMedCrossRef
163.
Verdejo HE, et al. Comparison of a radiofrequency-based wireless pressure sensor to swan-ganz catheter and echocardiography for ambulatory assessment of pulmonary artery pressure in heart failure. J Am Coll Cardiol. 2007;50(25):2375–82.PubMedCrossRef
164.
Lutembacher R. De la tenose mitrale avec communication interauirulaier. Arch Mal Coeur Vaiss. 1916;9:237–60.
165.
Hasenfuss G, et al. A transcatheter intracar diac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016;387(10025):1298–304.PubMedCrossRef
166.
Morris DA, Vaz Perez A, Blaschke F, Eichstadt H, Ozcelik C, Haverkamp W. Myocardial systolic and diastolic consequences of left ventricular mechanical dyssynchrony in heart failure with normal left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging. 2012;13(7):556–67.PubMedCrossRef
167.
Biering-Sorensen T, et al. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. Eur J Heart Fail. 2017;19(8):1043–52.PubMedCrossRef
168.
Tschöpe C, et al. Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond. Eur J Heart Fail. 2019;21(1):14–22.PubMedCrossRef
169.
Krum H, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof of-principle cohort study. Lancet. 2009;373(9671):1275–81.PubMedCrossRef
170.
Donazzan L, et al. Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clin Res Cardiol. 2016;105(4):364–71.PubMedCrossRef
171.
Schirmer SH, et al. Atrial remodeling following catheter-based renal denervation occurs in a blood pressure and heart rate-independent manner. JACC Cardiovasc Interv. 2015;8(7):972–80.PubMedCrossRef
172.
Patel HC, et al. Renal denervation in heart failure with preserved ejection fraction (RDT-PEF): a randomized controlled trial. Eur J Heart Fail. 2016;18(6):703–12.PubMedCrossRef
173.
174.
Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction: new approaches to diagnosis and management. Clin Cardiol. 2020;43(2):145–55.PubMedCrossRef
175.
Iyngkaran P, et al. The heart failure with preserved ejection fraction conundrum-redefining the problem and finding common ground? Curr Heart Fail Rep. 2020;17(2):34–42.PubMedCrossRef
176.
Packer M. Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. Eur J Heart Fail. 2020;22(2):214–27.PubMedCrossRef
177.
Borlaug BA. Exercise haemodynamics and outcome in patients with dyspnoea. Eur Heart J. 2014;35:3085–7.PubMedCrossRef
Metadata
Title
Heart failure with preserved ejection fraction based on aging and comorbidities
Authors
Ying Lin
Shihui Fu
Yao Yao
Yulong Li
Yali Zhao
Leiming Luo
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02935-x

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue

Research

Characterization of genomic alterations in Chinese colorectal cancer patients with liver metastases

Protocol

Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale

Research

Phase angle and Mediterranean diet in patients with acne: Two easy tools for assessing the clinical severity of disease

Research

Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer

Research

Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era

Protocol

Sulfur amino acid restriction, energy metabolism and obesity: a study protocol of an 8-week randomized controlled dietary intervention with whole foods and amino acid supplements
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits